Targeted Excellence
AI-based drug and biomarker solutions
Targeted Excellence
AI-based drug and biomarker solutions
We combine artificial intelligence and human knowledge to identify new therapeutic solutions
in silico drug discovery
BIOMARKER IDENTIFICATION
in-house machine learning
clinical trial design
in silico drug discovery
BIOMARKER IDENTIFICATION
in-house machine learning
clinical trial design
in silico drug discovery
BIOMARKER IDENTIFICATION
in-house machine learning
clinical trial design
in silico drug discovery
BIOMARKER IDENTIFICATION
in-house machine learning
clinical trial design
in silico drug discovery
BIOMARKER IDENTIFICATION
in-house machine learning
clinical trial design
in silico drug discovery
BIOMARKER IDENTIFICATION
in-house machine learning
clinical trial design
in silico drug discovery
BIOMARKER IDENTIFICATION
in-house machine learning
clinical trial design
in silico drug discovery
BIOMARKER IDENTIFICATION
in-house machine learning
clinical trial design
We combine artificial intelligence and human knowledge to identify new therapeutic solutions
What we do
AI-Powered Tailored Solutions for Pharma
AI-Powered Tailored Solutions for Pharma
We are an AI company focused on optimizing the drug discovery and development cycle to help more medications reach patients at lower costs.
We are an AI company focused on optimizing the drug discovery and development cycle to help more medications reach patients at lower costs.
How we do it
How we do it
Unlocking New Therapeutic Potential
Unlocking New Therapeutic Potential
Boolzi offers B2B AI and cheminformatics services to the pharmaceutical sector, combining advanced machine learning algorithms with human expertise.
Boolzi offers B2B AI and cheminformatics services to the pharmaceutical sector, combining advanced machine learning algorithms with human expertise.
Our approach involves two general strategies: to lower drug development costs and improve accessibility to innovative medications on a global scale:
Repurposing shelved compounds for new therapeutic indications, enhancing the value of pharmaceutical companies' proprietary libraries.
Applying AI to detect complex biomarkers and design clinical trials with increased chances of success.
Our approach involves two general strategies: to lower drug development costs and improve accessibility to innovative medications on a global scale:
Repurposing shelved compounds for new therapeutic indications, enhancing the value of pharmaceutical companies' proprietary libraries.
Applying AI to detect complex biomarkers and design clinical trials with increased chances of success.
FORGING TOMORROW'S CURES -
FORGING TOMORROW'S CURES -
FORGING TOMORROW'S CURES -
FORGING TOMORROW'S CURES -
Our Mission
Contribute to the development of new medicines accessible to patients.
Our Mission
Contribute to the development of new medicines accessible to patients.
Our Mission
Contribute to the development of new medicines accessible to patients.
Our Vision
We strive to lead in innovative medication development by using AI to revitalize pharmaceutical libraries and design informed clinical trials, ultimately reducing costs and increasing global accessibility.
Our Vision
We strive to lead in innovative medication development by using AI to revitalize pharmaceutical libraries and design informed clinical trials, ultimately reducing costs and increasing global accessibility.
Our Vision
We strive to lead in innovative medication development by using AI to revitalize pharmaceutical libraries and design informed clinical trials, ultimately reducing costs and increasing global accessibility.
Challenge
The Problem Revealed
The Problem Revealed
Over the past 25 years, pharmaceutical investments have grown steadily. However, for every 10,000 molecules investigated, only one reaches the market as a new drug.
This low productivity highlights the inefficiencies in the drug development pipeline, where most candidates fail during the process.
These challenges not only slow innovation but also impose significant economic burdens, with costs ultimately passed on to patients through approved medications.
Over the past 25 years, pharmaceutical investments have grown steadily. However, for every 10,000 molecules investigated, only one reaches the market as a new drug.
This low productivity highlights the inefficiencies in the drug development pipeline, where most candidates fail during the process.
These challenges not only slow innovation but also impose significant economic burdens, with costs ultimately passed on to patients through approved medications.
For every new drug introduced to the market, 9,999 are disregarded.
Only 1 in 10 drug candidates that enter clinical trials get approved.
The economic cost of failure is transferred to approved medications.
For every new drug introduced to the market, 9,999 are disregarded.
Only 1 in 10 drug candidates that enter clinical trials get approved.
The economic cost of failure is transferred to approved medications.
For every new drug introduced to the market, 9,999 are disregarded.
Only 1 in 10 drug candidates that enter clinical trials get approved.
The economic cost of failure is transferred to approved medications.
For every new drug introduced to the market, 9,999 are disregarded.
Only 1 in 10 drug candidates that enter clinical trials get approved.
The economic cost of failure is transferred to approved medications.
For every new drug introduced to the market, 9,999 are disregarded.
Only 1 in 10 drug candidates that enter clinical trials gets approved.
The economic cost of failure is transferred to approved medications.
Our Technology
Hybridization of in-house machine learning and human intelligence
Hybridization of in-house machine learning and human intelligence
Hybridization of in-house machine learning and human intelligence
Our algorithms can also be adapted to identify complex biomarkers and design informed clinical trials with improved recruitment and enhanced success.
Our algorithms can also be adapted to identify complex biomarkers and design informed clinical trials with improved recruitment and enhanced success.
Step 1
Data curation and processing
The client can provide its own data or Boolzi can gather and curate data from external sources.
Step 2
Algorithm training and validation
Using in house AI tools, Boolzi trains algorithms which are adapted to the client needs.
Step 3
Prediction
The trained and validated algorithms provide predictions, which are analyzed by human experts.
Step 4
Technical Report
The client receives our technical report with the predictions and validation figures, plus personalized advice.
Step 5
Post-Service Support
We have a long-term commitment to our clients, providing technical support beyond the initial report.
Step 1
Data curation and processing
The client can provide its own data or Boolzi can gather and curate data from external sources.
Step 2
Algorithm training and validation
Using in house AI tools, Boolzi trains algorithms which are adapted to the client needs.
Step 3
Prediction
The trained and validated algorithms provide predictions, which are analyzed by human experts.
Step 4
Technical Report
The client receives our technical report with the predictions and validation figures, plus personalized advice.
Step 5
Post-Service Support
We have a long-term commitment to our clients, providing technical support beyond the initial report.
Step 1
Data curation and processing
The client can provide its own data or Boolzi can gather and curate data from external sources.
Step 2
Algorithm training and validation
Using in house AI tools, Boolzi trains algorithms which are adapted to the client needs.
Step 3
Prediction
The trained and validated algorithms provide predictions, which are analyzed by human experts.
Step 4
Technical Report
The client receives our technical report with the predictions and validation figures, plus personalized advice.
Step 5
Post-Service Support
We have a long-term commitment to our clients, providing technical support beyond the initial report.
Our Unique Approach
What makes Boolzi different?
What makes Boolzi different?
Innovative Machine Learning Pipelines
The Boolzi team has developed versatile machine learning pipelines that are subject to permanent optimization and adapted to the client needs and data availability.
Proven Efficiency and Efficacy in Algorithms
Our algorithms have proven to be efficient and efficacious in benchmarking exercises and real-world applications. The predictions are analyzed by expert human eyes.
A People-Oriented Approach
We value and promote long-term relationships with our team members, our partners, and clients. Our commitment goes beyond the term of a contract.
Our Unique Approach
What makes
Boolzi different?
Innovative Machine Learning Pipelines
The Boolzi team has developed versatile machine learning pipelines that are subject to permanent optimization and adapted to the client needs and data availability.
Proven Efficiency and Efficacy in Algorithms
Our algorithms have proven to be efficient and efficacious in benchmarking exercises and real-world applications. The predictions are analyzed by expert human eyes.
A People-Oriented Approach
We value and promote long-term relationships with our team members, our partners, and clients. Our commitment goes beyond the term of a contract.
Partners
Partners
Our Services
Our Services
At Boolzi, we offer a diverse range of services tailored to empower businesses and drive innovation.
At Boolzi, we offer a diverse range of services tailored to empower businesses and drive innovation.
In Silico-Aided Drug discovery
Clinical Trial Design
Antisense Oligonucleotides Design
ADME-Tox Prediction
Biomarker identification
In Silico-Aided Drug discovery
Clinical Trial Design
Antisense Oligonucleotides Design
ADME-Tox Prediction
Biomarker identification
In Silico-Aided Drug discovery
Clinical Trial Design
Antisense Oligonucleotides Design
ADME-Tox Prediction
Biomarker identification
In Silico-Aided Drug discovery
Clinical Trial Design
Antisense Oligonucleotides Design
ADME-Tox Prediction
Biomarker identification
Clinical Trial Design
In Silico-Aided Drug discovery
ADME-Tox Prediction
Biomarker identification
Antisense Oligonucleotides Design
Latest News
Latest News
Dive into our news section to uncover stories about our projects, industry insights, and company culture.
Dive into our news section to uncover stories about our projects, industry insights, and company culture.
Press Releases
Press Releases
Discover the latest happenings, milestones, and insights. From groundbreaking innovations to exciting partnerships, stay informed with our press releases.
Discover the latest happenings, milestones, and insights. From groundbreaking innovations to exciting partnerships, stay informed with our press releases.
Nov 1, 2024
New strategic Partner: ApoyoDravet
This collaboration focuses on the development of specific drugs for this genetic disease, based on the latest progress in understanding the molecular bases of Dravet syndrome and innovative modes of action for potential new therapies.Dec 10, 2024
New strategic Parner: SCN8A Spain
Together, we will jointly address the search for new therapeutic solutions for epileptic encephalopathy due to SCN8A, a rare genetic disorder that causes drug-resistant seizures, developmental delay, and autistic features.
Nov 1, 2024
New strategic Partner: ApoyoDravet
This collaboration focuses on the development of specific drugs for this genetic disease, based on the latest progress in understanding the molecular bases of Dravet syndrome and innovative modes of action for potential new therapies.Dec 10, 2024
New strategic Parner: SCN8A Spain
Together, we will jointly address the search for new therapeutic solutions for epileptic encephalopathy due to SCN8A, a rare genetic disorder that causes drug-resistant seizures, developmental delay, and autistic features.
Nov 1, 2024
New strategic Partner: ApoyoDravet
This collaboration focuses on the development of specific drugs for this genetic disease, based on the latest progress in understanding the molecular bases of Dravet syndrome and innovative modes of action for potential new therapies.Dec 10, 2024
New strategic Parner: SCN8A Spain
Together, we will jointly address the search for new therapeutic solutions for epileptic encephalopathy due to SCN8A, a rare genetic disorder that causes drug-resistant seizures, developmental delay, and autistic features.
Meet the Team Behind Boolzi
Meet the Team
Behind Boolzi
Meet the Team
Behind Boolzi
We're a group of diverse talents united by passion and purpose. Together, we're driven to innovate and make an impact.
We're a group of diverse talents united by passion and purpose. Together, we're driven to innovate and make an impact.
We're a group of diverse talents united by passion and purpose.
Together, we're driven to innovate and make an impact.
Get in Touch
Get in Touch
Have questions, feedback, or interested in our services? We're here to help! Feel free to reach out to our team via the contact form. We look forward to hearing from you and discussing how we can collaborate.
Have questions, feedback, or interested in our services? We're here to help! Feel free to reach out to our team via the contact form. We look forward to hearing from you and discussing how we can collaborate.